Personal information

No personal information available

Activities

Collapse all

Employment (7)

Akademiska sjukhuset: Uppsala, SE

2012-12 to present | Specialist (Geriatric department)
Employment
Source: Self-asserted source
Martin Ingelsson

Uppsala University: Uppsala, SE

2005-01-01 to present (Public Health and Caring Sciences)
Employment
Source: Self-asserted source
Martin Ingelsson

University of Toronto: Toronto, CA

2020-01-05 to 2020-07-04 | Visiting Professor
Employment
Source: Self-asserted source
Martin Ingelsson

Massachusetts General Hospital: Boston, MA, US

2014-08-01 to 2015-07-31 | Sabbatical (Neurology)
Employment
Source: Self-asserted source
Martin Ingelsson

Akademiska sjukhuset: Uppsala, SE

2005-01 to 2012-12 | Residency (Geriatric department)
Employment
Source: Self-asserted source
Martin Ingelsson

Massachusetts General Hospital: Boston, MA, US

2001-10-01 to 2004-12-31 | Post Doc (Neurology)
Employment
Source: Self-asserted source
Martin Ingelsson

Karolinska Universitetsjukhuset i Huddinge: Huddinge, SE

1998-05 to 2001-05 | Internship
Employment
Source: Self-asserted source
Martin Ingelsson

Education and qualifications (2)

Karolinska Institutet: Stockholm, SE

1995-03-20 to 2001-09-28 | PhD
Education
Source: Self-asserted source
Martin Ingelsson

Karolinska Institutet: Stockholm, SE

1989-01-20 to 1995-06-15 | MD
Education
Source: Self-asserted source
Martin Ingelsson

Funding (6)

Alpha-synuclein oligomers as a novel target for therapy and diagnostics in Parkinson’s disease and related disorders

2015 to 2017 | Grant
Parkinson Research Foundation (Stockholm, SE)
Source: Self-asserted source
Martin Ingelsson

Alfa-synuklein - ny målmolekyl för framtida behandling av Parkinsons sjukdom

2014 to 2015 | Grant
Brain Foundation (Stockholm, SE)
Source: Self-asserted source
Martin Ingelsson

Alpha-synuclein oligomers as a novel target for therapy and diagnostics in Parkinson’s disease and related disorders

2014 to 2015 | Grant
Swedish Parkinson Foundation (Stockholm, SE)
Source: Self-asserted source
Martin Ingelsson

Development of biomarkers for Parkinson´s disease and other neurodegenerative disorders with Lewy body pathology

2014 to 2015 | Grant
Swedish Research Council Formas (Stockholm, SE)
Source: Self-asserted source
Martin Ingelsson

Investigation on the propagation and aggregation of alpha-synuclein - implications for future immunotherapy in Lewy body disorders

2014 to 2015 | Grant
Swedish Alzheimer Foundation (Stockholm, SE)
Source: Self-asserted source
Martin Ingelsson

Utveckling av monoklonala antikroppar mot alfa-synuklein protofibriller - nya möjligheter till diagnostik och behandling av Parkinsons sjukdom och relaterade tillstånd

2012 to 2015 | Grant
Marianne and Marcus Wallenberg Foundation (Stockholm, SE)
Source: Self-asserted source
Martin Ingelsson

Works (9)

Correction to: Molecular Therapeutics in Development to Treat Alzheimer’s Disease

Molecular Diagnosis & Therapy
2025-01 | Journal article
DOI: 10.1007/s40291-024-00752-8
Contributors: Maria Carmela Tartaglia; Martin Ingelsson
Source: check_circle
Crossref

Dual-ligand fluorescence microscopy enables chronological and spatial histological assignment of distinct amyloid-β deposits

Journal of Biological Chemistry
2025-01 | Journal article
DOI: 10.1016/j.jbc.2024.108032
Contributors: Therése Klingstedt; Hamid Shirani; Farjana Parvin; Sofie Nyström; Per Hammarström; Caroline Graff; Martin Ingelsson; Ruben Vidal; Bernardino Ghetti; Dag Sehlin et al.
Source: check_circle
Crossref

Molecular Therapeutics in Development to Treat Alzheimer’s Disease

Molecular Diagnosis & Therapy
2025-01 | Journal article
DOI: 10.1007/s40291-024-00738-6
Contributors: Maria Carmela Tartaglia; Martin Ingelsson
Source: check_circle
Crossref

Plasma Protein Profiling of Incident Cardiovascular Diseases: A Multisample Evaluation

Circulation: Genomic and Precision Medicine
2023-12 | Journal article
DOI: 10.1161/CIRCGEN.123.004233
Contributors: Lars Lind; Olga Titova; Rui Zeng; Daniela Zanetti; Martin Ingelsson; Stefan Gustafsson; Johan Sundström; Johan Ärnlöv; Sölve Elmståhl; Themistocles Assimes et al.
Source: check_circle
Crossref

Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic α-synuclein mouse models of neurodegenerative disease

Exploration of Neuroprotective Therapy
2023-10-30 | Journal article
DOI: 10.37349/ent.2023.00053
Contributors: Bianca Vlcek; Sylvie Dumas; Sara Ekmark-Lewén; Eleonora Rubino; Martin Ingelsson; Åsa Wallén-Mackenzie
Source: check_circle
Crossref

The G51D SNCA mutation generates a slowly progressive α-synuclein strain in early-onset Parkinson’s disease

Acta Neuropathologica Communications
2023-05-03 | Journal article
DOI: 10.1186/s40478-023-01570-5
Contributors: Heather H. C. Lau; Ivan Martinez-Valbuena; Raphaella W. L. So; Surabhi Mehra; Nicholas R. G. Silver; Alison Mao; Erica Stuart; Cian Schmitt-Ulms; Bradley T. Hyman; Martin Ingelsson et al.
Source: check_circle
Crossref

Single-cell transcriptomics of resected human traumatic brain injury tissues reveals acute activation of endogenous retroviruses in oligodendroglia

2022-09-09 | Preprint
DOI: 10.1101/2022.09.07.506982
Contributors: Raquel Garza; Yogita Sharma; Diahann Atacho; Arun Thiruvalluvan; Sami Abu Hamdeh; Marie Jönsson; Vivien Horvath; Anita Adami; Martin Ingelsson; Patric Jern et al.
Source: check_circle
Crossref

Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice

Brain and Behavior
2022-07 | Journal article
DOI: 10.1002/brb3.2628
Contributors: Agata Aniszewska; Joakim Bergström; Martin Ingelsson; Sara Ekmark‐Lewén
Source: check_circle
Crossref

Large‐Scale Plasma Protein Profiling of Incident Myocardial Infarction, Ischemic Stroke, and Heart Failure

Journal of the American Heart Association
2021-12-07 | Journal article
DOI: 10.1161/JAHA.121.023330
Contributors: Lars Lind; Daniela Zanetti; Martin Ingelsson; Stefan Gustafsson; Johan Ärnlöv; Themistocles L. Assimes
Source: check_circle
Crossref

Peer review (7 reviews for 4 publications/grants)

Review activity for Molecular neurodegeneration (2)
Review activity for Nature communications (1)
Review activity for Science. (1)
Review activity for Translational neurodegeneration. (3)
How many people are using ORCID?